【摘要】 目的评价布地奈德和美沙拉嗪对活动期炎症性肠病的疗效及其对Th17细胞及白细胞介素-23(IL-23)的影响。方法 66例活动期炎症性肠病患者分为试验组和对照组各33例。对照组口服美沙拉嗪治疗,每次1g,每天4次。试验组在对照组的基础上吸入布地奈德200~1600μg·d-1联合治疗。治疗2个月后,对其临床疗效、Th17细胞水平及IL-23进行评价。结果试验组患者的治疗总有效率(93.93%)显著高于对照组(67.67%,P<0.05)。试验组轻、中、重患者的Th17分别为(2.05±0.36),(2.59±1.09),(3.48±2.05),显著低于对照组的(2.33±0.51),(3.26±1.23),(4.67±2.27)(P<0.05)。试验组轻、中、重患者的IL-23水平分别为(208.3±28.7),(619.4±34.5),(1276.8±59.7),显著低于对照组的(276.9±34.8),(698.3±47.8),(1356.3±71.6)(P<0.05)。结论布地奈德和美沙拉嗪治疗活动期炎症性肠病效果良好,能有效降低Th17细胞和IL-23水平。更多还原

【Abstract】 Objective To evaluate the clinical effect and impact of Th17 cells and interleukin- 23( IL- 23) by the treatment of budesonide and mesalazine in active inflammatory bowel disease. Methods Sixty- six patients with active inflammatory bowel disease were randomly divided into control and treatment groups,each group was 33 cases. Patients in control group were treated with mesalazine 1 g,four times each day. Patients in treatment group was treated with budesonide 200- 1600 μg · d- 1on the basis of control group. The efficacy,Th17 cells and IL- 23 levels were compared after two months treatment. Results Total effective rate of treatment group( 93. 93%) was significantly lower than the control group( 67. 67%,P <0. 05). Th17 cells levels of mild,moderate,severe patients in treatment group were( 2. 05 ± 0. 36),( 2. 59 ± 1. 09),( 3. 48 ± 2. 05),significantly lower than that in control group,which were( 2. 33 ± 0. 51),( 3. 26 ± 1. 23),( 4. 67 ±2. 27)( P < 0. 05); IL- 23 levels in treatment group were( 208. 3 ± 28. 7),( 619. 4 ± 34. 5),( 1276. 8 ± 59. 7),significantly lower than that in control group( 276. 9 ± 34. 8),( 698. 3 ± 47. 8),( 1356. 3 ± 71. 6)( P < 0. 05). Conclusion The clinical efficacy of budesonide and mesalazine for the treatment of active inflammatory bowel diseaseis was good,and can effectively reduce the level of Th17 cells and IL- 23.更多还原